Advertisement
Advertisement

TOVX

TOVX logo

Theriva Biologics, Inc.

0.23
USD
Sponsored
+0.01
+4.62%
Aug 10, 15:59 UTC -4
Closed
exchange

After-Market

0.23

0.00
-0.43%

TOVX Earnings Reports

Positive Surprise Ratio

TOVX beat 35 of 41 last estimates.

85%

Next Report

Today
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.05
Implied change from Q1 26 (Revenue/ EPS)
-100.00%
/
--
Implied change from Q2 25 (Revenue/ EPS)
--
/
-91.07%

Theriva Biologics, Inc. earnings per share and revenue

On May 05, 2026, TOVX reported earnings of -0.05 USD per share (EPS) for Q1 26, beating the estimate of -0.05 USD, resulting in a 1.96% surprise. Revenue reached 300.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a +0.50% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.05 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
logo
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
logo
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
logo
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
logo
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
logo
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
logo
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
logo
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
logo
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
logo
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
For Q1 2026, Theriva Biologics, Inc. reported EPS of -$0.05, beating estimates by 1.96%, and revenue of $300.00K, 0% as expectations.
The stock price moved up 0.5%, changed from $0.38 before the earnings release to $0.38 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 4 analysts, Theriva Biologics, Inc. is expected to report EPS of -$0.05 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement